Travere Therapeutics (TVTX) Short-term Investments (2013 - 2018)

Travere Therapeutics has reported Short-term Investments for 6 years, with the latest figure at $166.4 million in Q2 2018.

• For the quarter ending Q2 2018, Short-term Investments fell 19.51% year-over-year to $166.4 million; the trailing twelve-month figure through Jun 2018 stood at $166.4 million (down 19.51% YoY), and the FY2017 full-year result was $201.2 million, down 6.35% from the prior year.
• Short-term Investments for Q2 2018 stood at $166.4 million, down from $202.9 million in the prior quarter.
• The five-year high for Short-term Investments was $250.4 million in Q3 2016, with the low at $5.9 million in Q2 2015.
• Historically, Short-term Investments has averaged $148.3 million across 5 years, with a median of $199.7 million in 2016.
• Annual changes were most pronounced in 2014 — Short-term Investments surged 7085.29% — and 2018, when it retreated 19.51%.
• Travere Therapeutics' Short-term Investments stood at $9.6 million in 2014, then soared by 1907.11% to $191.8 million in 2015, then rose by 12.03% to $214.9 million in 2016, then fell by 6.35% to $201.2 million in 2017, then fell by 17.32% to $166.4 million in 2018.
• The last three Short-term Investments figures came in at $166.4 million (Q2 2018), $202.9 million (Q1 2018), and $201.2 million (Q4 2017), per Business Quant data.